M Mencoboni
Overview
Explore the profile of M Mencoboni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Canova S, Ceresoli G, Grosso F, Zucali P, Gelsomino F, Pasello G, et al.
ESMO Open
. 2022 Dec;
7(6):100644.
PMID: 36463732
Background: Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum-pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint...
2.
Camerini A, Banna G, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, et al.
Clin Transl Oncol
. 2018 Nov;
21(6):790-795.
PMID: 30448956
Purpose: Metronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advanced non-small cell lung cancer (NSCLC) based on its safety profile and high patient compliance. Methods:...
3.
Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, et al.
Ann Oncol
. 2018 Mar;
29(5):1258-1265.
PMID: 29514216
Background: Tumor immune microenvironment (TME) plays a key role in malignant pleural mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune checkpoint inhibitors as anticancer approach. This study...
4.
Mencoboni M, Filiberti R, Taveggia P, Bruzzone A, Garuti A, Del Corso L, et al.
Neoplasma
. 2017 Jan;
64(2):253-261.
PMID: 28043153
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become a treatment after first-line chemotherapy in patients with advanced NSCLC. We assessed the predictive and prognostic role of EGFR and...
5.
Ceresoli G, Grosso F, Zucali P, Mencoboni M, Pasello G, Ripa C, et al.
Br J Cancer
. 2014 Jun;
111(2):220-6.
PMID: 24918816
Background: The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. There are no specific guidelines for their management. Methods: The clinical records of elderly patients (⩾70 years...
6.
Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, et al.
Med Oncol
. 2013 Dec;
31(1):797.
PMID: 24307348
Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall...
7.
Ceresoli G, Zucali P, Mencoboni M, Botta M, Grossi F, Cortinovis D, et al.
Br J Cancer
. 2013 Jul;
109(3):552-8.
PMID: 23860535
Background: The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin...
8.
Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, et al.
Br J Cancer
. 2012 Jan;
106(4):658-65.
PMID: 22240782
Background: The FAST is a 2 × 2 factorial trial addressing two questions: (1) the role of replacing cisplatin (P) with a non-platinum agent, vinorelbine (N), and (2) the role...
9.
Murialdo R, Bertolotti F, Pastorino G, Mencoboni M, Bergaglio M, Folco U, et al.
Cancer Chemother Pharmacol
. 2011 Feb;
68(4):1009-16.
PMID: 21327683
Purpose: Bi-weekly gemcitabine (G) in combination with docetaxel (D) is an effective treatment for metastatic breast cancer (MBC) previously treated with adjuvant/neoadjuvant anthracyclines containing regimens with a good toxicity profile....
10.
Mencoboni M, Grillo-Ruggieri F, Salami A, Scasso F, Rebella L, Grimaldi A, et al.
Eur J Cancer Care (Engl)
. 2010 May;
20(4):503-7.
PMID: 20477856
Concurrent chemoradiotherapy has become the standard of care for patients with inoperable squamous cell head and neck carcinoma. More recently, induction chemotherapy has been adopted as an approach in the...